Logo-aim
Arch Iran Med March. 2020;23(3): 150-154.
  Abstract View: 205
  PDF Download: 343

Original Article

Descriptive Epidemiology of Lymphoma in Northern Iran: Results from the Golestan Registry 2004–2013

Nastaran Jafari-Delouei 1, Mohammad Naeimi-Tabiei 2 * ORCID logo, Abdolreza Fazel 3, Mohammad Ashaari 4, Ehsan Hatami 5, Seyed Mehdi Sedaghat 6, Mohammad Poorabbasi 7, Susan Hasanpour-Heidari 1, Fatemeh Ghasemi-Kebria 1, Faezeh Salamat 1, Abbas Moghaddami 3, Masoomeh Gholami 7, Freddie Bray 8, Gholamreza Roshandel 1

1 Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
2 Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran
3 Omid Cancer Research Center, Omid Preventive Medicine and Heath Promotion Center, Golestan University of Medical Sciences, Gorgan, Iran
4 Department of Pathology, Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran
5 Mirdamad Radiotherapy and Chemotherapy Center, Gorgan, Iran
6 Deputy of Public Health, Golestan University of Medical Sciences, Gorgan, Iran
7 Death Registry Unit, Deputy of Public Health, Golestan University of Medical Sciences, Gorgan, Iran
8 Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France

Abstract

Background: There is currently little known about the epidemiology of lymphomas in Iran. The aim of this paper is to describe the geographic and time variations in incidence rates of lymphomas in the Golestan province between 2004 and 2013.

Methods: The Golestan Population-based Cancer Registry (GPCR) routinely registers primary cancer patients from all sources (e.g. pathology centers, hospitals, etc.) throughout the Golestan province. We obtained data on newly-diagnosed lymphomas in Golestan during 2004-2013 from the GPCR dataset. Crude rates and age standardized incidence (ASR) rates (per 100000) of lymphomas were estimated, joinpoint regression was used to quantify incidence trends and average annual percent changes (AAPCs) were calculated.

Results: In total, 898 new cases of lymphoma were registered in the GPCR during 2004-2013. The ASR of Hodgkin lymphoma (HL) was 1.5 and 1.1 in males and females, respectively, while corresponding non-Hodgkin lymphoma (NHL) rates were greater, at 6.5 and 3.4 in males and females, respectively. Our results indicated a significant difference in the trends of HL between males (AAPC = -3.2) and females (AAPC = 3.6, P value = 0.001). The incidence rates of lymphoma were considerably higher in the urban population (ASR = 7.3) compared to those residing in rural areas (ASR = 5.3, P value = 0.054). We also found higher incidence rates for both HL and NHL in the western parts of the Golestan province.

Conclusion: The incidence rates of lymphoma in the Golestan province are relatively high and vary geographically, with a higher incidence observed in the western area. Such differences may reflect unknown lifestyle and environmental determinants linked to ethnic susceptibility differing between the two areas.

Keywords: Epidemiology, Hodgkin Disease, Iran, Non-Hodgkin’s Lymphoma
Cite this article as: Jafari-Delouei N, Naimi-Tabiei M, Fazel A, Ashaari M, Hatami E, Sedaghat SM, et al. Descriptive epidemiology of lymphoma in Northern Iran: results from the Golestan Registry 2004–2013. Arch Iran Med. 2020;23(3):150–154.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 205

Your browser does not support the canvas element.


PDF Download: 343

Your browser does not support the canvas element.